Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 32, 2720-2725, December 1, 1972]
© 1972 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tobey, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tobey, R. A.

Effects of Cytosine Arabinoside, Daunomycin, Mithramycin, Azacytidine, Adriamycin, and Camptothecin on Mammalian Cell Cycle Traverse1

Robert A. Tobey

Biomedical Research Group, Los Alamos Scientific Laboratory, University of California, Los Alamos, New Mexico 87544

Six chemotherapeutic agents were tested for effects on mammalian cell cycle traverse in synchronized cultures of Chinese hamster cells. Cytosine arabinoside was found to inhibit DNA synthesis, as well as to reduce grossly the rate of progression from G1 into S. At low dosage levels, daunomycin and adriamycin had only a slight effect upon entry of cells into S, but they were almost totally effective in preventing cells from reaching mitosis, and 5-azacytidine greatly inhibited progression into S phase. However, cells already in S at the time azacytidine was added continued to synthesize DNA but were unable to progress to mitosis. Entry into S was hardly affected by mithramycin, while completion of G2 was partially inhibited, although the sensitivity of G2 processes was much less pronounced in mithramycin-treated cells than in cells treated with daunomycin or adriamycin. Camptothecin allowed initiation of DNA synthesis, but it effectively prevented cells from progressing to mitosis in the incubation period allotted in the test protocol.

1 This study was supported by Contract NIH-CR-(71)-56 from Chemotherapy, National Cancer Institute, NIH, under interagency agreement with the United States Atomic Energy Commission.

Received 5/23/72. Accepted 9/ 5/72.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
P. Fiorani, J. F. Amatruda, A. Silvestri, R. H. Butler, M.-A. Bjornsti, and P. Benedetti
Domain Interactions Affecting Human DNA Topoisomerase I Catalysis and Camptothecin Sensitivity
Mol. Pharmacol., December 1, 1999; 56(6): 1105 - 1115.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Ohdo, T. Makinosumi, T. Ishizaki, E. Yukawa, S. Higuchi, S. Nakano, and N. Ogawa
Cell Cycle-Dependent Chronotoxicity of Irinotecan Hydrochloride in Mice
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1383 - 1388.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
W. A. Cliby, K. A. Lewis, K. K. Lilly, and S. H. Kaufmann
S Phase and G2 Arrests Induced by Topoisomerase I Poisons Are Dependent on ATR Kinase Function
J. Biol. Chem., January 4, 2002; 277(2): 1599 - 1606.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1972 by the American Association for Cancer Research.